Statement Of Financial Position [Abstract]

OSE Immunotherapeutics - Filing #2813125

Concept	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Statement of financial position [abstract]
Assets [abstract]
Property, plant and equipment	743,000 EUR	—	—	—	—	—	—	926,000 EUR	—	—	—	—	—	—	—	—	—	—
Intangible assets other than goodwill	48 784 EUR	—	—	—	—	—	—	51 122 EUR	—	—	—	—	—	—	—	—	—	—
Deferred tax assets	182,000 EUR	—	—	—	—	—	—	173,000 EUR	—	—	—	—	—	—	—	—	—	—
Cash and cash equivalents	25 620 EUR	—	—	—	—	—	—	33 579 EUR	—	—	—	—	29 368 EUR	—	—	—	—	—
Assets	91 781 EUR	—	—	—	—	—	—	101 876 EUR	—	—	—	—	—	—	—	—	—	—
Equity and liabilities [abstract]
Equity [abstract]
Issued capital	3 705 EUR	—	—	—	—	—	—	3 705 EUR	—	—	—	—	—	—	—	—	—	—
Share premium	65 611 EUR	—	—	—	—	—	—	65 605 EUR	—	—	—	—	—	—	—	—	—	—
Treasury shares	549,000 EUR	—	—	—	—	—	—	160,000 EUR	—	—	—	—	—	—	—	—	—	—
Equity	32 658 EUR	65 611 EUR	549,000 EUR	3 705 EUR	220,000 EUR	35 890 EUR	160,000 EUR	47 890 EUR	65 605 EUR	150,000 EUR	3 705 EUR	21 111 EUR	61 364 EUR	3 597 EUR	7 485 EUR	93,000 EUR	104,000 EUR	65 449 EUR
Liabilities [abstract]
Deferred tax liabilities	1 514 EUR	—	—	—	—	—	—	1 748 EUR	—	—	—	—	—	—	—	—	—	—
Equity and liabilities	91 781 EUR	—	—	—	—	—	—	101 876 EUR	—	—	—	—	—	—	—	—	—	—